ClinicalTrials.gg
RecruitingNCT07040566Updated Dec 17, 2025

A Trial of Varenicline for E-cigarette Cessation

A Phase 2 interventional study of Varenicline 1mg BID and Placebo in E-cigarette Use, Vaping and Nicotine Dependence, sponsored by Yale University. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by Yale University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
326
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies in Vaping by Yale University — 6 open to participants now, 6 under way, none of them phase 3. Vaping · Yale University.

Planned enrollment
3rd of 21
326 · median 60
Started
2025
with 4 others
Phase 2
4 of 22
2 open now
Registered
18th of 22
by date

Among the 22 studies in Vaping by Yale University, this one is the 3rd largest by planned enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2025, is one of 4 in phase 2, and was the 18th registered.

Vaping

404 studies on the registry are indexed under Vaping; 97 are open to participants now.

Browse Vaping studies →

Open to participants now

6 of the 22 studies in Vaping by Yale University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 65 Vaping studies recruiting now, 33 (51%) set no upper age limit and 31 (48%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Vaping by Yale University, or all of them as a file.
02

Study summary

This is randomized, placebo-controlled clinical trial in treatment-seeking adults who report regular e-cigarette use to test the hypothesis that varenicline is efficacious for quitting e-cigarettes.

Read the detailed description

Participants will randomly be assigned to 12-weeks of varenicline (titrated to 2mg daily) or matching placebo plus brief cessation advice from a counselor and self-management resources. All participants will also complete research assessments every 3 weeks during treatment and a final follow-up visit at week 26.

The primary objective is to test the efficacy of varenicline vs. placebo on e-cigarette quit rates. We will also evaluate predictors and moderators of outcomes and explore changes in health biomarkers following e-cigarette cessation treatment.

03

Conditions studied

  • E-cigarette Use
  • Vaping
  • Nicotine Dependence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • report daily use of an e-cigarette containing nicotine
  • live in Connecticut or South Carolina

Exclusion criteria

Exclusion Criteria:

  • regular use of other tobacco products besides e-cigarettes
  • medical for varenicline use
  • current treatment for tobacco cessation
  • lack proficiency in English
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
326 participants (estimated)

Study arms

  • Experimental
    Varenicline

    Participants will randomly be assigned to 12-weeks of varenicline (titrated to 2mg daily) plus brief cessation advice with a counselor and self-management resources.

    Drug: Varenicline 1mg BID

  • Placebo comparator
    Placebo

    Participants will randomly be assigned to 12-weeks of matching placebo plus brief cessation advice with a counselor and self-management resources.

    Drug: Placebo

Interventions

  • DrugVareniclineStudies of VareniclineVarenicline pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    12 weeks following the standard titration of 1 mg, twice daily

  • DrugPlacebo

    Matching placebo twice daily

06

What researchers measure

Primary outcomes

  1. Number of Participants Abstinent From E-cigarette Use at Week 12

    7-day point-prevalence e-cigarette abstinence (PPA) at Week 12 defined as no ecigarette use \[and no use of any combusted tobacco product\], not even a puff, biochemically verified by saliva cotinine

    Time frame: Week 12

Secondary outcomes

  1. Number of Participants Abstinent From E-cigarette Use at Week 26

    7-day point-prevalence e-cigarette abstinence (PPA) at Week 26 defined as no ecigarette use \[and no use of any combusted tobacco product\], not even a puff, biochemically verified by saliva cotinine

    Time frame: Week 26

07

Study locations

2 of 2 sites recruiting
  • Yale Cancer Center/Smilow Cancer Hospital at Yale-New Haven
    New Haven, Connecticut 06520, United States
    Recruiting
  • Hollings Cancer Center at MUSC (HCC)
    Charleston, South Carolina 29425, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data will be shared to an NIH data repository - the NIMH Data Archive

Supporting information: Study protocol, Statistical analysis plan

Access criteria: Access to the data is managed by the NIMH Data Archive

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jul 2030, 57 months after the start.

Of 16 phase 2 interventional studies under Vaping, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 37. This study's planned 57 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2025
First posted
Jun 27, 2025
StartActual
Oct 14, 2025
Primary completionEst.
Jul 30, 2030
CompletionEst.
Oct 30, 2030
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07040566
Lead sponsor
Yale University
Responsible party
Sponsor
First posted
Jun 27, 2025
Start date
Oct 14, 2025
Primary completion
Jul 30, 2030 (estimated)
Completion
Oct 30, 2030 (estimated)
Last update
Dec 17, 2025

Study contacts

Lisa Fucito, PhD
Contact
lisa.fucito@yale.edu
2032001470
Michael Fatigate, PhD
Contact
Michael.fatigate@yale.edu
Lisa Fucito, PhD
principal investigator · Yale University
Benjamin Toll, PhD
principal investigator · Medical University of South Carolina

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Varenicline

Start the discussion